#Switzerland #NLS Pharmaceutics #Zurich #Kadimastem #IsletRx

NLS Pharmaceutics and Kadimastem Enhance Diabetes Care with Hong Kong Patent

NLS Pharmaceutics Ltd., a biopharmaceutical firm based in Switzerland, and its merger partner Kadimastem Ltd. have recently announced a significant breakthrough in diabetes treatment technology. On September 4, 2025, they revealed that the Hong Kong Intellectual Property Department granted Kadimastem a patent covering its unique cell-selection and enrichment technology utilized in their groundbreaking IsletRx program. This patent marks a vital expansion of intellectual property protection for the company in an essential market for diabetes treatment.

Significance of the Patent

The Hong Kong patent augments previously acquired patents in Europe, the United States, and India, reinforcing global protections surrounding IsletRx. This innovative technology aims to select and enrich functional islet cells derived from stem cells, providing a foundation for a potential cure for insulin-dependent diabetes.

Alexander Zwyer, the CEO of NLS Pharmaceutics, celebrated this achievement, emphasizing the strategic importance of expanding intellectual property into Hong Kong, which is a pivotal hub for life sciences within Asia. As diabetes presents a rising concern, this milestone is vital for fostering clinical development and subsequent patient accessibility.

The international diabetes statistics illustrate the relevance of this patent. According to the International Diabetes Federation, approximately 706,000 adults in Hong Kong were living with diabetes as of 2024, representing a prevalence rate of 8.2%. The growing number of diabetes cases in the region underscores the urgent need for innovative treatment options like IsletRx.

Economic Impact

The healthcare costs associated with diabetes are staggering. Data from recent studies indicate that lifetime healthcare expenditures for individuals diagnosed with diabetes average $125,000. When this figure is applied to Hong Kong's diabetes population, it results in a projected economic impact of around $90 billion, highlighting the financial burden this disease imposes on the healthcare system and society.

About IsletRx

The IsletRx platform is designed to produce a scalable source of insulin-producing cells that can mimic the natural secretion of insulin and glucagon in response to glucose levels in the blood. This approach addresses some of the core challenges faced in diabetes management and offers hope for improved patient outcomes through functional endocrine cell transplantation.

Company Profiles

NLS Pharmaceutics

NLS Pharmaceutics Ltd. focuses on developing innovative therapeutic agents to treat disorders related to the central nervous system and other related conditions. The company aims to tackle complex health issues through advanced therapy solutions.

Kadimastem

Kadimastem Ltd. is leading in clinical-stage cell therapy development, specifically focused on creating off-the-shelf cell products aimed at treating neurodegenerative diseases and diabetes. The company strives to bridge cells and therapy to generate transformative treatment methods.

Conclusion

The newfound patent in Hong Kong is a landmark achievement for both NLS Pharmaceutics and Kadimastem. It not only strengthens their intellectual property portfolio but also signifies a step forward in their shared mission to combat diabetes. With a significant population affected by the disease and substantial economic repercussions worldwide, advancements like IsletRx could potentially make a meaningful difference in patient care and management of diabetes.

Together, these companies are on the verge of potentially redefining diabetes treatment, making the pursuit of innovation in this space more critical than ever.